

Pfizer Inc.	CE-210666
Mechanism of Action	5-Hydroxytryptamine 1B receptor (5-HT _{1B}) antagonist http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=2 http://www.ncbi.nlm.nih.gov/gene/3351
Overview	CE-210666 is a potent (K _i = 1.2 nM), selective (125-fold over 5-HT _{1A} ; 740-fold over hERG; ≥ 1000-fold over dopamine reuptake), inverse agonist (functional antagonist) of the human 5-HT _{1B} receptor. Nerve terminal autoreceptors of the 5-HT _{1B} subtype negatively modulate transmitter release.
Safety/Tolerability	CE-210666 has completed single-dose toleration studies in healthy volunteers – a maximum tolerated dose of 60 mg was determined. Nonclinical toxicology data support clinical studies up to 2 weeks in duration.
Additional Information	A PET ligand study in healthy adults demonstrated that central receptors were saturated by CE-210666 after a single dose of 30 mg. Further development of this compound was discontinued when the lead elzasonan (less selective for 5-HT _{1B}) in combination with sertraline (SSRI) failed to demonstrate efficacy sufficiently superior to sertraline alone in Major Depressive Disorder.
Suitable for and Exclusions	Limited duration studies in humans (see Safety/Tolerability section above). The lead compound, elzasonan (CP-448187), while less 5-HT _{1B} selective, may be more suitable for multiple-dose efficacy studies.
Clinical Trials	http://clinicaltrials.gov/ct2/results?term=elzasonan
Publications	http://www.ncbi.nlm.nih.gov/pubmed/18691129 http://issx.confex.com/issx/15na/webprogram/Paper11299.html